Skip to main content

Table 3 Association between cfDNA measurements and blood pressure levels (non-hypertensive and hypertensive), body mass index or lymphovascular space invasion in 60 endometrial cancer patients

From: Serum DNA integrity index as a potential molecular biomarker in endometrial cancer

LSVI and blood pressure status in ECs qPCR-Alu115 (ng/ml)
Median
Mean
P –Value
Mann-Whithey
qPCR-Alu247 (ng/ml)
Median
Mean
P –Value
Mann-Whithey
DNA integrity index
Median
Mean
P –Value
Mann-Whithey
LSVI negative (LVSI-) 23.98
48.9
0.54 3.58
7.2
0.25 0.14
0.16
0.03
LSVI positive (LVSI+) 30.61
49.4
6.56
11.1
0.22
0.27
Non-hypertensive 26.34
32.99
0.38 4.89
7.4
0.78 0.19
0.23
0.04
Hypertensive 42.97
53.35
4.84
12.5
0.13
0.15
LSVI- non-hypertensive 22.05
43.7
0.58 4.43
7.06
0.70 0.14
0.17
0.77
LSVI- hypertensive 28.45
60.5
3.63
8.29
0.13
0.14
LSVI+ non-hypertensive 29.02
39.1
0.44 6.11
8.90
0.55 0.23
0.32
0.05
LSVI+ hypertensive 71.53
66.4
14.01
14.6
0.14
0.18
BMI < 30 20.35
37.59
0.25 5.10
8.51
0.76 0.17
0.22
0.01
BMI ≥ 30 26.96
46.47
3.53
7.13
0.11
0.12
LSVI- BMI < 30 16.81
29.60
0.16 3.18
6.86
0.50 0.14
0.17
0.17
LSVI- BMI ≥ 30 28.45
62.66
3.63
7.78
0.11
0.12
LSVI+ BMI < 30 32.75
51.43
0.82 6.82
12.13
0.63 0.22
0.30
0.29
LSVI+ BMI ≥ 30 26.78
43.12
4.25
7.88
0.21
0.18
  1. Median, mean and Mann–Whitney U test for cfDNA values obtained from qPCR-Alu115, qPCR-Alu247 and DNA integrity index (qPCR-Alu247/qPCR-Alu115) in samples from hypertensive and non-hypertensive patients, from patients with BMI < 30 and ≥30, and from LVSI negative (LVSI-) and positive (LVSI+) tumors
  2. LVSI Limphovascular Space Invasion, BMI Body Mass Index